ClinicalTrials.gg
Not yet recruitingNCT07727096EMPOWER-HFpEFUpdated Jul 27, 2026

Exercise-Based Cardiac Rehabilitation for Patients With Heart Failure With Preserved Ejection Fraction (EMPOWER-HFpEF)

An interventional study of Exercise-Based Cardiac Rehabilitation and Guideline-Directed Medical Therapy in HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction and Readmission Rates, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Fundación para la Investigación del Hospital Clínico de Valencia · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia — 5 open to participants now, 6 under way, 1 of them phase 3. Heart Failure · Fundación para la Investigación del Hospital Clínico de Valencia.

Planned enrollment
Largest of 14
390 · median 64
Started
2026
the only one that year
No phase
7 of 14
4 open now
Registered
14th of 14
by date

Among the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, this one has the largest planned enrollment, is the only one that started in 2026, is one of 7 with no phase, and was the 14th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, or all of them as a file.
02

Study summary

Heart failure with preserved ejection fraction (HFpEF) is a common condition among older adults. It is associated with frequent hospitalizations, impaired functional capacity, reduced quality of life, and high healthcare utilization. Despite recent advances in pharmacological therapy, many patients continue to experience recurrent clinical deterioration and functional decline. Exercise-based cardiac rehabilitation has demonstrated benefits in improving physical performance and quality of life. Still, its effect on long-term clinical outcomes in patients with high-risk HFpEF has not been established.

The EMPOWER-HFpEF study is a multicenter, randomized, controlled trial designed to evaluate whether an early, individualized, multimodal exercise-based cardiac rehabilitation program improves clinical outcomes compared with usual care in patients with HFpEF. Eligible participants will be randomly assigned in a 1:1 ratio to receive either usual care alone or usual care plus a structured 12-month exercise-based cardiac rehabilitation program. The intervention includes an initial 6-month supervised phase, followed by a 6-month hybrid phase combining supervised sessions with structured home- or community-based exercise to promote long-term adherence and maintenance of physical activity.

The primary objective is to determine whether this rehabilitation strategy reduces adverse clinical outcomes, including all-cause mortality, heart failure hospitalizations, all-cause hospitalizations, and outpatient heart failure decompensation, while improving functional capacity and health-related quality of life over 12 months. The results of this study will provide evidence on the effectiveness of a long-term multimodal exercise-based cardiac rehabilitation program as part of the comprehensive management of patients with HFpEF.

Read the detailed description

Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and is associated with a high burden of recurrent hospitalizations, impaired functional capacity, and reduced health-related quality of life. Despite advances in guideline-directed medical therapy, many patients continue to experience recurrent clinical events and progressive functional decline. Exercise-based cardiac rehabilitation has demonstrated consistent benefits on exercise capacity and quality of life in patients with heart failure; however, robust evidence regarding its impact on long-term clinical outcomes in patients with HFpEF remains limited, particularly in high-risk populations.

EMPOWER-HFpEF is a multicenter, prospective, randomized, controlled clinical trial designed to evaluate the effectiveness of an early, individualized, multimodal exercise-based cardiac rehabilitation program in patients with high-risk HFpEF. Eligible participants will be randomly assigned in a 1:1 ratio to receive either guideline-directed medical therapy alone or guideline-directed medical therapy plus a structured exercise-based cardiac rehabilitation program. The intervention will be delivered over 12 months and consists of an initial 6-month supervised phase, followed by a 6-month hybrid phase that combines supervised and home-based exercise, with the to promote long-term adherence and maintenance of physical activity.

Participants will be followed for 12 months. The study is designed to determine whether this rehabilitation strategy improves clinically relevant outcomes while preserving functional status and health-related quality of life. The results are expected to provide evidence to support the integration of long-term exercise-based cardiac rehabilitation into the routine management of patients with HFpEF.

03

Conditions studied

  • HF - Heart Failure
  • HFpEF - Heart Failure With Preserved Ejection Fraction
  • Readmission Rates
  • Exercise Training
  • Cardiac Rehab

Browse trials for

Keywords

  • Heart Failure with Preserved Ejection Fraction
  • Cardiac Rehabilitation
  • Quality of Life
  • Readmission
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Diagnosis of heart failure with preserved (HFpEF) according to current clinical guidelines, defined by: a) signs and/or symptoms of heart failure; b) left ventricular ejection fraction ≥50%; c) elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) (≥220 pg/mL); and, d) objective evidence of structural and/or functional cardiac abnormalities consistent with HFpEF.
  • High-risk clinical profile, defined by at least one of the following: a) hospitalization for acute or worsening heart failure within the previous 120 days; b) outpatient worsening heart failure within the previous 120 days requiring emergency department evaluation or intensification of oral or intravenous diuretic therapy in a specialized heart failure clinic; c) recent diagnosis of symptomatic HFpEF (≤120 days) with (NYHA) functional class II-III; or d) stable symptomatic HFpEF (NYHA class II-III) with at least two of the following comorbidities: hypertension, diabetes mellitus, obesity ( ≥30 kg/m²), chronic kidney disease, dyslipidemia, obstructive sleep apnea, or stable coronary artery disease, together with elevated NT-proBNP (≥220 pg/mL in patients in sinus rhythm or ≥600 pg/mL in patients with atrial fibrillation).
  • Clinically stable at the time of enrollment, with no requirement for intravenous therapy or major changes in heart failure treatment during the previous 2 weeks.
  • Considered by the investigator to be able to participate in a structured exercise-based cardiac rehabilitation program safely.
  • Able and willing to provide written before any study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  • Inability to safely participate in a structured exercise-based cardiac rehabilitation program because of severe neurological or musculoskeletal disorders, significant cognitive impairment, or severe psychiatric illness that, in the opinion of the investigator, would interfere with study participation.
  • Clinically unstable heart failure at the time of enrollment, defined by the need for intravenous therapy, recent major changes in heart failure treatment, or ongoing heart failure decompensation.
  • Severe valvular heart disease considered to be the primary cause of the patient's symptoms.
  • Acute coronary syndrome, unstable angina, or coronary revascularization within the previous 2 weeks.
  • Uncontrolled hypertension, defined as resting systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg, or resting heart rate ≥110 beats/min despite guideline-directed medical therapy.
  • Severe primary pulmonary disease predominantly limiting functional capacity, including significant pulmonary hypertension, chronic thromboembolic pulmonary disease, or severe .
  • Primary cardiomyopathy or known infiltrative heart disease.
  • Severe non-cardiac comorbidity associated with an estimated of less than 1 year, in the opinion of the investigator.
  • Inability to provide written or to comply with study procedures and follow-up requirements.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
390 participants (estimated)

Study arms

  • Active comparator
    Guideline-Directed Medical Therapy

    Participants receive guideline-directed medical therapy, regular follow-up in the heart failure clinic, lifestyle education, and individualized recommendations for home-based physical activity, in accordance with current clinical practice.

    Other: Guideline-Directed Medical Therapy

  • Experimental
    Exercise-Based Cardiac Rehabilitation

    Participants receive guideline-directed medical therapy plus a structured 12-month exercise-based cardiac rehabilitation program consisting of a 6-month supervised phase followed by a 6-month hybrid supervised and home-based phase.

    Behavioral: Exercise-Based Cardiac Rehabilitation · Other: Guideline-Directed Medical Therapy

Interventions

  • BehavioralExercise-Based Cardiac Rehabilitation

    A structured, individualised, multimodal exercise-based cardiac rehabilitation program delivered over 12 months. The intervention includes aerobic exercise, resistance training, inspiratory muscle training, and lifestyle counselling. It consists of an initial 6-month supervised phase, followed by a 6-month hybrid phase that combines supervised and home-based exercise to promote long-term adherence and maintenance of physical activity.

  • OtherGuideline-Directed Medical Therapy

    Participants receive guideline-directed medical therapy according to current heart failure guidelines, regular follow-up in the heart failure clinic, lifestyle education, and individualized recommendations to maintain regular physical activity as part of routine clinical care.

06

What researchers measure

Primary outcomes

  1. Hierarchical composite clinical outcome (win ratio)

    Comparison between treatment groups using a hierarchical composite endpoint analyzed according to the win ratio method. The hierarchical endpoint includes, in order of priority, all-cause mortality, heart failure hospitalization, all-cause hospitalization, outpatient heart failure decompensation without hospitalization, days alive and out of hospital, change in physical function assessed by the Short Physical Performance Battery (SPPB; total score range 0-12, with higher scores indicating better physical function), and change in health-related quality of life assessed by the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS; score range 0-100, with higher scores indicating better health status).

    Time frame: 12 months

Secondary outcomes

  1. All-Cause Mortality

    Occurrence of death from any cause.

    Time frame: 12 months

  2. Heart Failure Hospitalization or Outpatient Heart Failure Decompensation

    Occurrence of hospitalization for worsening heart failure or outpatient heart failure decompensation not requiring hospitalization.

    Time frame: 12 months

  3. All-Cause Hospitalization

    Occurrence of hospitalization for any cause.

    Time frame: 12 months

  4. Health-Related Quality of Life

    Change from baseline in health-related quality of life assessed using the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS). Scores range from 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline and 12 months

  5. Physical Function

    Change from baseline in physical function assessed using the Short Physical Performance Battery (SPPB). The SPPB total score ranges from 0 to 12 points, with higher scores indicating better lower extremity physical performance and functional status.

    Time frame: Baseline and 12 months

Other outcomes

  1. Peak Oxygen Uptake

    Change from baseline in peak oxygen uptake (peak VO₂), measured by symptom-limited cardiopulmonary exercise testing and expressed as mL/kg/min, in a predefined subgroup of approximately 80 participants.

    Time frame: Baseline and 12 months

  2. Left Ventricular Diastolic Function

    Change from baseline in left ventricular filling pressure, assessed by transthoracic echocardiography using the average E/e' ratio, calculated from septal and lateral mitral annular early diastolic velocities. Unit of Measure: Average E/e' ratio (unitless)

    Time frame: Baseline and 12 months

  3. Right Ventricular Systolic Function

    Change from baseline in right ventricular systolic function, assessed by transthoracic echocardiography using tricuspid annular plane systolic excursion (TAPSE). Unit of Measure: millimetres (mm)

    Time frame: Baseline and 12 months

  4. Left Ventricular End-Diastolic Volume Index

    Change from baseline in left ventricular end-diastolic volume index (LVEDVi) measured by transthoracic echocardiography using the biplane Simpson method and indexed to body surface area. Unit of Measure: millilitres per square meter (mL/m²)

    Time frame: Baseline and 12 months

  5. Estimated Pulmonary Artery Systolic Pressure

    Change from baseline in estimated pulmonary artery systolic pressure (PASP) assessed by transthoracic echocardiography using the peak tricuspid regurgitation velocity and estimated right atrial pressure. Unit of Measure: millimetres of mercury (mmHg)

    Time frame: Baseline and 12 months

  6. Heart Failure Biomarker: N-terminal Pro-B-type Natriuretic Peptide

    Change from baseline in circulating N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration. Unit of Measure: pg/mL

    Time frame: Baseline and 12 months

  7. Heart Failure Biomarker: Carbohydrate Antigen 125

    Change from baseline in circulating carbohydrate antigen 125 (CA125) concentration. Unit of Measure: U/mL

    Time frame: Baseline and 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data relevant to the published study findings will be considered for sharing following an appropriate request, subject to applicable institutional policies and ethical and legal requirements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: De-identified individual participant data and supporting documents will be considered for sharing following publication of the primary study results, for a period to be determined in accordance with institutional policies and applicable regulations.

Access criteria: Access to de-identified individual participant data and supporting documentation will be considered upon reasonable request. Requests will be reviewed on a case-by-case basis by the study investigators in accordance with institutional policies, ethical requirements, and applicable legal and regulatory frameworks. Access may require a data sharing agreement

Data sharing details ↗ · www.incliva.es

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2031, 60 months later.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 60 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 27, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 1, 2031
CompletionEst.
Sep 1, 2031
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07727096
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Collaborators
Generalitat Valenciana
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2031 (estimated)
Completion
Sep 1, 2031 (estimated)
Last update
Jul 27, 2026

Study contacts

Patricia Fernández Saiz, PhD
Contact
patricia.fernandez@incliva.es
96 162 89 18

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion